MONTREAL, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cerro de Pasco Resources Inc. (TSXV CDPR) (OTCQB GPPRF) (FRA N8HP) (the Company or CDPR) is pleased to provide an operational review and corporate update highlighting key workstreams completed and consolidated at the Quiulacocha Tailings Project, as the Company transitions toward the next stage of project execution. This update builds on the technical and permitting progress outlined in the Company’s December 10, 2025 news release and reflects the completion and i ...

公司核心进展 - PDS Biotechnology公司已向美国食品药品监督管理局提交了其III期VERSATILE-003临床试验方案的修正案 [1] - 该修正案将无进展生存期更改为一个可以更早评估的主要终点，并具有显著的统计学效力，这可能为PDS0101的加速批准提供基础 [1] - 中位总生存期仍然是完全批准的主要终点，这与FDA最初的建议一致 [1] 监管沟通与支持依据 - 此次提交是基于2025年12月与FDA举行的一次建设性的C类会议，会议讨论了PDS0101针对HPV16阳性复发性和/或转移性头颈癌的加速批准路径 [2] - 该修正案得到了公司VERSATILE-002试验积极最终结果的支持，该试验显示了有希望的中位总生存期和持久的无进展生存期 [2] 管理层观点与战略意义 - 公司管理层认为，将无进展生存期纳入主要终点为缩短VERSATILE-003试验的持续时间提供了重要机会 [3] - 修正案保留了中位总生存期和安全性作为获得FDA完全批准的要求 [3] - 基于2025年12月与监管机构的对话，公司相信已获得一条可能加速其监管提交的路径 [3] 公司业务与研发管线 - PDS Biotechnology是一家后期免疫治疗公司，专注于改变免疫系统靶向和杀死癌症的方式 [4] - 公司已启动一项关键临床试验，以推进其针对晚期HPV16阳性头颈部鳞状细胞癌的主要研发项目 [4] - 其主要研究性靶向免疫疗法PDS0101正在与标准护理免疫检查点抑制剂联合开发，同时也作为三联疗法的一部分进行开发，该三联疗法还包括PDS01ADC和一种标准护理免疫检查点抑制剂 [4]

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options THE WOODLANDS, TX, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced new subgroup clinical data from its PoC study presented at the 2026 ASCO Gastrointestinal (G ...

- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC IRVINE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced an expedited timeline for the topline data readout now expected in the first half of 2026 for the Phase 3 PIVOT-006 clinical trial comparing adjuvant ...

Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo CapitalInitial financing tranche of over $6 million, which we expect will provide cash runway into the third quarter of 2026 enabling funding through potential NDA acceptance decision by the FDA, with two additional financing tranches totaling over $22 million contingent on NDA acceptance and NDA approval by the FDACompletion of this financing ...

Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects to Report One-Year Cohort 1 Data and Early Cohort 2 Data from RIDGE™-1 Study of TN-401 for PKP2-Associated ARVC in First Half of 2026 Plans to Pursue Alignment on Regulatory Pathways for Lead Gene Therapy Programs in 2026 Raised $60 Million in 4Q25 to Support Runway Through mid-2027 SOUTH SAN FRANCISCO, Calif., Jan ...

Geneva, Switzerland, Jan. 09, 2026 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, and a subsidiary of WISeKey International Holding AG (Nasdaq: WKEY; SIX: WIHN) (“WISeKey”), today announced that it has reached a final, binding agreement with Kaynes SemiCon to establish SEALKAYNESQ Ltd, a Joint Venture (“JV”) in India. The JV is being formed with the obje ...

NANO Nuclear Energy Inc. NANO Nuclear Energy Announces Dismissal of Federal Securities Lawsuit. Dismissal of Federal Securities Class Action Lawsuit Follows Dismissal of Related Shareholder Derivative Lawsuit. Dismissal of Federal Securities Class Action Lawsuit Follows Dismissal of Related Shareholder Derivative Lawsuit New York, NY, Jan. 09, 2026 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor (MMR) and tech ...

文章核心观点 - 公司董事长在致股东信中总结了2025年的重大进展与战略成就 并对未来关键矿物、铜和黄金的需求前景表示乐观 强调公司通过技术突破、组织优化和政府合作 致力于巩固美国关键矿物供应链并提升股东价值 [1][5][6] 2025年主要成就总结 - **勘探技术突破**：在红岩峡谷金矿项目进行了广泛的槽道采样 发现了品位极高的金矿化验结果 高达107.5克/吨和60.0克/吨 并将已知矿化延伸了100英尺 同时识别出六个宽度超过2英尺的新碧玉岩透镜体 [3] - **成功完成3D激发极化(IP)测量**：2025年6月启动覆盖约10英亩、探测深度达500英尺的先进3D IP测量 10月获得超预期结果 通过高电阻率和与硫化物矿化相关的高IP值 高精度绘制了含金矿脉 该技术有助于量化矿脉厚度、走向和倾角 优化未来钻探计划 [3] - **董事会增强**：2025年12月任命Matt Westbrook为董事会成员 其拥有关键矿物开发、国家安全投资和美国政府合作方面的丰富背景 加强了公司与联邦国内资源安全优先事项的战略协同 [3] - **战略公司重组**：2025年11月宣布对采矿权主张进行重组 在Liberty Star Hay Mountain Holdings LLC下成立专注子公司：专注于多矿物铜矿权的Earp Ridge Mines LLC、专注于世界级黄金目标的Red Rock Mines LLC 以及新定义的American Strategic Minerals实体 该结构提升了运营清晰度、资产差异化和针对性合资机会 [3] - **政府倡导与互动**：基于在华盛顿特区与多位议员工作人员的会晤 推动了美国关键矿物需求的认知 最终促成国会议员在7月致关键内阁部长的信函 重点提及Hay Mountain项目并敦促联邦加快对亚利桑那州采矿计划的支持 [3] - **完成SAM注册**：2025年6月成功在联邦奖项管理系统注册 为获得联邦拨款和合同打开了大门 增强了公司参与政府保障战略矿物国内来源项目的资格 [3] 项目与资产概述 - **旗舰项目**：Hay Mountain项目 包含红岩峡谷金矿项目、Earp Ridge铜矿项目和新成立的American Strategic Minerals 位于以斑岩铜-金-钼系统闻名的地区 展现出巨大潜力 [1][6] - **资产定位**：公司资产组合中的关键矿物 包括用于电气化的铜、用于电子产品和储备的黄金 以及钼和稀土等相关元素 对于减少美国对外国供应商的依赖至关重要 [5] 行业前景与公司展望 - **需求驱动**：清洁能源转型、技术创新和地缘政治因素推动关键矿物、铜和黄金需求前景异常光明 全球铜需求预计到2050年将翻倍 黄金在经济不确定性中保持其避险资产地位 [5] - **公司计划**：2026年计划利用有利形势 推进针对性钻探、寻求战略合作伙伴关系并探索拨款机会 以进一步圈定资源并创造股东价值 同时预期通过简化的许可和激励措施获得持续的联邦支持 [5]

Permit Renewal Increases Potential Throughput to Approximately 1.2 Million Gallons Annually and Strengthens Long-Term Strategic Positioning at Perma-Fix NorthwestATLANTA, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced that it has received a final Dangerous Mixed Waste Permit Renewal for its Perma-Fix Northwest (PFNW) Mixed Waste Facility (MWF) located in Richland, Washington. The permit, issued by the Washington Department of Ecology ( ...